SAKK 41/13


Aspirin for the prevention of recurrent colorectal cancer

A number of studies show that patients with colorectal cancer who regularly take low-dose aspirin experience a more favourable disease progression than patients who do not. This is particularly true of patients with a modified PI3K gene (PIK3CA mutation) in their tumour cells. In such patients, aspirin is believed to reduce the risk of a recurrence (relapse) after treatment for colorectal cancer. However, the results of current investigations into the role played by aspirin were compiled retrospectively and are somewhat equivocal. This is why the SAKK is now conducting its own study.
In the SAKK 41/13 trial, patients who have been treated for colorectal cancer and who are known to have a PIK3CA mutation will take aspirin or placebo every day for three years. They will be randomly assigned to the aspirin or placebo group, with two thirds of patients receiving aspirin and one third receiving placebo.

M. Joerger -  'SAKK 41/13 is the first study to test aspirin in selected colon cancer patients harbouring activating PIK3CA mutations'


Contact
Coordinating Investigator: Prof. Dr. med Ulrich Güller, MHS, FEBS Phone: +41 71 494 11 11
Medical Oncology Fax: +41 71 494 63 25
Cantonal Hospital St. Gallen ulrich.gueller@kssg.ch

Supporting Coordinating
Investigators: PD Dr. med Dr. rer nat Markus Joerger Phone: +41 76 559 10 70
Medical Oncology Fax: +41 71 494 63 25
Cantonal Hospital, St. Gallen markus.joerger@kssg.ch


Page last updated on 02-05-2016

Sakk.ch